Last reviewed · How we verify
OTT166
At a glance
| Generic name | OTT166 |
|---|---|
| Also known as | nesvategrast |
| Sponsor | OcuTerra Therapeutics, Inc. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Nesvategrast (OTT166) in Diabetic Retinopathy (DR) (PHASE2)
- Safety and Exploratory Efficacy Study of SF0166 in the Treatment of Neovascular Age-Related Macular Degeneration (AMD) (PHASE1, PHASE2)
- Safety and Exploratory Efficacy Study of SF0166 for the Treatment of Diabetic Macular Edema (DME) (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- OTT166 CI brief — competitive landscape report
- OTT166 updates RSS · CI watch RSS
- OcuTerra Therapeutics, Inc. portfolio CI